qXR-CTR vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A automates cardiothoracic ratio measurement from chest X-rays to assess general heart size and potential heart failure risk. Conversely, Tool B analyzes echocardiogram video clips for the early detection of a specific condition, cardiac amyloidosis. While both are AI-powered tools within cardiology, they utilize different imaging modalities and address distinct diagnostic needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
qXR-CTR by Qure.ai automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. EchoGo Amyloidosis by Ultromics is an AI-powered screening tool designed for the early detection of cardiac amyloidosis from echocardiogram video clips.
qXR-CTR analyzes chest X-ray images, specifically posterior-anterior (PA) view chest X-rays. EchoGo Amyloidosis analyzes echocardiogram video clips, requiring a single apical 4-chamber view.
qXR-CTR provides an automated measurement of the cardiothoracic ratio (CTR), along with annotation lines on the X-ray image and structured reports. EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on the analysis of echocardiographic markers, and has demonstrated high diagnostic accuracy with 85% sensitivity and 93% specificity.